Tonix Pharmaceuticals Stock News

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.

As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significance Over Placebo on the Primary Endpoint of Reduction in Daily Pain in RALLY Study

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) did not significantly reduce fibromyalgia daily pain at Week 14 compared

Tonix Pharmaceuticals (NASDAQ: TNXP ) reported its Q4 earnings results on Monday, March 14, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Tonix Pharmaceuticals missed estimated earnings by 16.67%, reporting … Full story available on Benzinga.com

Tonix Pharmaceuticals press release (TNXP): Q4 GAAP EPS of -$0.07 misses by $0.01.As of December 30, 2021, Tonix had $178.7 million of cash and cash equivalents

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder

CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointme

CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics. In this role, Dr. Rosenfeld will direct Tonix’s pharmacogenomics efforts including applying artificial intelligence, genome-wide association studies and mathematical modeling techniques to the analysis of patient outcomes in Tonix’s clinical trials.

NEW YORK , March 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VEON, NIO, RIG, CLOV, and TNXP. … Full story available on Benzinga.com

Full story available on Benzinga.com

An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022

An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022 Binge Eating Disorder is Estimated to Affect 2.8 Million American Adults1-3 Expands Uses of Tonix’s Proprietary Potentiated Oxytocin for Intranasal Administration to a Potential New Indication CHATHAM, N.J., March 07, 2022 (GLOBE NEWSWIRE) — Tonix … The post Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder appeared first on ForexTV .

Buyers are unwinding their trades in a big way, following through on the profit-taking they initiated yesterday.

Buyers are unwinding their trades in a big way, following through on the profit-taking they initiated yesterday.